Immunomodulatory imide drugs (IMiDs) such as thalidomide and its derivatives lenalidomide, pomalidomide, and Iberdomide (CC-220) act as molecular glue degraders to promote the ubiquitination and degradation of IKZF1 and IKZF3 by CRL4CRBN, ultimately relieving the symptoms of SLE (134, 137, 138, 182) (Table 1). This evidence concerns the gene IKZF1 and systemic lupus erythematosus.